MiNK Therapeutics shared a post on X:
“MiNK Therapeutics will present new data at American Society of Gene and Cell Therapy (ASGCT26) Annual Meeting on agenT-797, highlighting adaptive immune modulation across cancer and ARDS. Advancing iNKT cell therapy to address areas of high unmet need.”
Other articles from MiNK Therapeutics on OncoDaily.